Joel T. Arcari
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
Microtubule and mitosis dynamics, Antibiotic Resistance in Bacteria, Asymmetric Synthesis and Catalysis, Cancer Treatment and Pharmacology, Synthetic Organic Chemistry Methods
Most-Cited Works
- → Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections(2012)97 cited
- → Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections(2011)97 cited
- → PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy(2010)87 cited
- → Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative Activity(2013)63 cited
- → A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19(2024)61 cited
- → Preparation and Properties of 2-Methyleneoxetanes(1999)56 cited
- → The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer(2007)25 cited
- → Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections(2012)20 cited
- → Discovery and characterization of a novel class of pyrazolopyrimidinedione tRNA synthesis inhibitors(2014)18 cited
- → Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease(2025)16 cited